Abelcet


Also found in: Dictionary, Encyclopedia, Wikipedia.
Related to Abelcet: Ambisome

Abelcet®

A liposomal preparation of amphotericin B, which somewhat reduces amphotericin’s side effects, which include high fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnoea and tachypnoea, drowsiness, generalised weakness, nephrotoxicity, hypokalaemia, hypomagnesaemia, hepatotoxicity, leukopaenia, thrombopaenia, cardiac arrhythmias—including ventricular fibrillation—and heart failure

Abelcet

A brand name for the antifungal drug AMPHOTERICIN B in a liquid complex. It is given by injection.
Mentioned in ?
References in periodicals archive ?
The company has developed or acquired a number of marketed products, including PEG-INTRON, marketed by Schering-Plough, and ABELCET, ONCASPAR, ADAGEN, and DEPOCYT, which are all marketed in North America by Enzon's hospital and oncology sales forces.
The doctor looked at one form of Abelcet and assumed It was the same dosage for the conventional Amphotericln," said Dr Rayner.
Dr Armen - who was brought in earlier this year to oversee a massive restructuring operation - said the Abelcet sale marked the first large asset to be disposed of under Elan's recovery plan, which, when put together with other sales, would mean the strategy was approximately one- third complete.
3% among Abelcet patients (serum creatinine is a laboratory marker of nephrotoxicity).
Neutropenic patients with unresolved fever after three days of antibacterial therapy were randomized (1:1:1) to receive either Abelcet 5 mg/kg/day (n=78), AmBisome 3 mg/kg/day (n=85), or AmBisome 5mg/kg/day (n=81).
The contract manufacturing segment includes contract manufacturing revenues related to services the Company provides for a number of customers who require injectable products, such as Abelcet for markets outside of Canada and the U.
This includes contract manufacturing revenues related to services the Company provides for customers who require injectable products, such as Abelcet for markets outside of Canada and the U.
This significant decrease for the fourth quarter and the full year of 2006 is a result of the Abelcet intangible assets write-down which was reported in the fourth quarter of 2005.
In the meantime," Baker continued, "we expect to continue to be operationally profitable from our Abelcet franchise.
The decrease is a result of the Abelcet intangible write-down which occurred in December 2005.